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Abstract. The present clinical study investigated the
role of protein adsorption on complement activation
and neutrophil functions during in vivo haemodialysis.
The parameters were measured simultaneously at the
arterial and venous sites of a cuprophan (CU) dialyser
with or without pretreatment with human albumin,
human immunoglobulins or human total plasma pro-
teins (PLP). Leukocyte count, complement activation
(C3a des arg), oxygen radical production and chemot-
axis were measured at time zero and 15 min at the
arterial and venous sites of the dialyser. Leukopenia
observed at both sites was prevented only with PLP
treatment. Complement activation was maximal at the
venous site, but was not prevented by any of the
treatments. Neutrophil oxygen radical production and
chemotaxis were significantly decreased only at the
venous site and restored to normal with any of the
three treatments. Complement activation was maximal
at the venous site, but was not prevented by any of
the treatments. Protein adsorption on the dialyser
membrane seems to modulate the bioincompatibility
parameters in a different way. Depending on the func-
tions tested, the protein fractions have different pro-
tecting effects, indicating the multifactorial mechanism
implicated in the CU haemodialysis-induced leukop-
enia, complement activation and neutrophil defect.
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Introduction
The transient leukopenia and neutrophil dysfunctions
occurring at the initiation of haemodialysis on cellu-
losic membranes have been mostly attributed to com-
plement activation [1-4]. However a discrepancy
between the degree of complement activation, leukop-
enia and neutrophil dysfunctions at the maximum of
leukopenia was reported [5,6]. These defects have not
been evidenced on synthetic membranes or after reuse
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of cellulosic membranes [7,8]. Moreover, neutrophil
defects were shown to be altered after 15 min of dialysis
only at the venous site of the cuprophan (CU) dialyser,
suggesting that the membrane contact itself could play
a role [9]. In addition adsorption of proteins on the
membrane surface seemed to interfere with these phen-
omena. Indeed, in vitro experiments showed a different
recovery of proteins which was by far the largest on
polysulphone (PS) followed by polyacrilonitrile (PAN)
and cuprophane (CU). In contrast the recovery of
proteins on polycarbonate (PC) was almost negligible
and this differential protein coating was found to alter
the neutrophil functional response [10].
Since the most marked changes in white blood cell
count, complement activation and neutrophil dysfunc-
tions were observed on the CU dialyser, we initiated a
clinical study of leukopenia, complement activation
and neutrophil functions measured simultaneously at
the arterial and venous sites with and without pretreat-
ment of the dialyser with human albumin (ALB),
human immunoglobulin (IG) or human total plasma
proteins (PLP) on the CU membrane.
Subjects and methods
Patients and procedure
Sixteen patients aged 30-75 years (mean 60), on chronic
haemodialysis for a mean of 48 months (range 6-181),
entered the study. The dialyser consisted of CF 15-11
(Travenol) made of CU. The CU membrane was either used
in its original set-up (five patients), or pretreated with a
solution of PLP (four patients), ALB (four patients) or IG
(three patients). The protein solutions used were diluted with
saline from inititial concentrated solutions (20%, Red Cross,
Bern) to concentrations of 5% for PLP, 4% for ALB and 4%
for IG. The coating procedure with the protein solutions was
initiated by flushing the dialyser with 11 saline. Two
hundred ml of the protein solution were then introduced into
the blood compartment of the dialyser and left within the
dialyser for 15 min at room temperature while no dialysate
was running. After 15 min of contact within the dialyser, the
protein solution was rinsed out with 1 1 saline. After this
treatment, the clinical dialysis session was started with blood
flow maintained at 250-300 ml/min while the dialysate, which
contained bicarbonate, had a flow rate of 500 ml/min in a
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single-pass mode. Heparin was administered at individually
adapted doses ranging from 2000 to 5000 U at the start of
dialysis and 500 to 750 U hourly thereafter.
Neutrophil preparation
Three to 6 ml blood samples (heparinized, lOU/ml) were
obtained from the patients' arteriovenous fistulae immedi-
ately before initiation of dialysis (Time 0), and from arterial
and venous sites of the dialyser 15 min after the onset of
dialysis. Leukocytes were counted in the total blood on an
automated analyser (Sysmex CC-800). Purified preparations
of more than 95% neutrophils were obtained in a single
centrifugation step on a discontinuous Percoll gradient
(76%/60%, volume/volume) as already described [6]. The
neutrophil population was identical whatever the group or
the time of the dialysis.
Oxygen radical determination
Luminol- and lucigenin-enhanced chemiluminescence (CL)
were used, the latter being a specific indicator of superoxide
production and the former being dependent on hydrogen
peroxide, other radicals and myeloperoxidase [11,12].
Appropriate stimuli were mixed with 5 x 104 neutrophils in
a volume of 500 ul of Hanks buffer supplemented with
56 umol/1 of luminol or 0.1 mmol/1 of lucigenin at 37 °C, and
the resulting light emission was measured in mV on a LKB
luminometer at 5 min intervals until peak CL was reached
(20-30 min), as described [7]. Opsonized zymosan (OZ) was
prepared as in [7] and used at a final concentration of
1.5 mg/ml.
Chemotaxis
Chemotaxis was assessed by the 'under agarose' method
exactly as described [13]. Four series of two wells were cut
in agarose which covered the bottom of culture dishes. The
outer well received 5 ul of the chemotactic factor or medium
and the inner well 5 ul of the cell suspension containing
2xlO7 cells/ml. Zymosan-activated plasma (ZAP), con-
taining C5a des Arg, which was prepared according
to [6], and formyl-methionyl-leucyl-phenylalanine (FMLP,
0.1 umol/1) were used as stimuli.
Complement activation
One ml blood sample obtained from the patients' arterio-
venous fistula was taken in tubes containing EDTA at a final
concentration of 10 mmol/1 just before the start of dialysis
and at 15 min at the arterial and venous site of the dialyser.
Tubes were immediately centrifuged (2000 g, 5 min, 4°C),
then plasma was collected and frozen at — 80 °C until ana-
lysis. C3a des arg concentrations were measured by radio-
immunoassay according to the manufacturer's instructions
(Hans Rahn & Co., Zurich, Dept Amersham).
Statistical analysis
Statistical analysis was performed using the paired /-test.
Individual values are represented.
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Results
Figure 1 illustrates the evolution of leukocyte counts
at Time 0 and 15 min of dialysis at the arterial and
venous sites. As already observed, no significant differ-
ence was evidenced between arterial and venous sites
at 15 min of dialysis [9]. Pretreatment with total PLP
corrected the leukopenia at the arterial site as well as
at the venous site. In contrast neither a solution of
ALB nor of IG prevented the leukocyte drop. This
was not due to a non-adhesiveness of ALB or IG on
the membrane. Indeed, after washing the protein-
coated dialyser with a saline solution, these proteins
were eluted from the dialyser in 200 ml of a solution
containing glycerol (10%), mercapto-ethanol (5%),
sodium dodecyl sulfate (2%) and Tris-HCl (0.0625 mol,
pH 6.8) and identified by sodium dodecylsulfate poly-
acrilamide gel electrophoresis (data not shown). The
protein recovery of 0.3% for PLP, 0.5% for ALB and
0.8% for IG did not correlate with the initial amount
introduced in the dialyser indicating that the type of
protein and the selective reactivity of the membrane
must play a role. Since an effect was observed at these
amounts of proteins, no other concentration of protein
was tested, except for ALB, which showed an identical
leukopenia using a 2% or 4% solution.
Although C5a is known as a better activator of
neutrophils than C3a, its great affinity for C5a recep-
tors and its rapid clearance makes it a less sensitive
cumulative marker. Indeed, at 15 min of dialysis, C5a
des arg was found to be less than lOng/ml at the
arterial site, while it increased up to 53 + 15.4 ng/ml at
the venous site. Complement activation was thus meas-
ured by the accumulation of C3a des arg and is shown
in Figure 2. Whatever the pretreatment method, the
C3a des arg levels were similar at 15 min to the levels
measured on a new uncoated CU membrane.
Moreover, the same significant differences were
observed at 15 min between the arterial and venous site.
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Fig. 1. Leukocyte count in patients at Time 0,15 min arterial site (A)
and 15 min venous site (V) during dialysis on a new cuprophane
membrane without treatment (NONE), pretreated with
albumin (ALB), total plasma proteins (PLP) or
immunoglobulins (IG)) as described under Methods.
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Fig. 2. Complement activation as measured by the C3a des arg levels
on a new CU or CU pretreated with ALB, PLP or IG, at Time 0,
15min arterial site and 15min venous site. Legends and abbrevi-
ations are as in Fig. 1.
Figure 3 shows the effect of different pretreatments
on oxygen radical production when stimulated with
OZ by neutrophils collected at 0 min and 15 min at
the arterial and venous site of the dialyser. Whether
luminol- (Figure 3a) or lucigenin- (Figure 3b)
enhanced CL was measured, coating the CU membrane
with either a solution of ALB, PLP or IG significantly
corrected the defect observed at the venous site
(P<0.05) of a new untreated membrane. When other
stimuli were used, such as phorbol myristate acetate
or FMLP, the defect observed at the venous site of
the dialyser was also corrected upon membrane pre-
treatment (data not shown).
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Fig. 3. Luminol- (a) and lucigenin- (b) amplified chemiluminescence
(CL) of neutrophils stimulated with opsonized zymosan on a new
CU or CU pretreated with ALB, PLP or IG. Legends and abbrevi-
ations are as in Fig. 1.
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Fig. 4. Random migration (a), migration stimulated with zymosan-
activated plasma (b) and FMLP (c) by neutrophils of patients
dialysed on CU membrane without treatment, or treated with ALB
or PLP. Legends and abbreviations are as in Fig. 1.
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Chemotaxis, random and stimulated with ZAP or
FMLP, is shown in Figures 4a, 4b, and 4c, respectively.
Again, a depressed response (P<0.05) was seen only
in cells collected at the venous site of a new untreated
CU membrane. Treatment with ALB or PLP was able
to correct this decreased response. A significant differ-
ence was observed between the random migration of
neutrophils in the ALB group compared to the PLP
group (.P<0.05). However, the random migration of
neutrophils measured in the three groups was within
the normal range determined in 21 healthy controls
(10-33 mm).
Discussion
Leukopenia, complement activation with elevation of
the anaphylatoxin C3a des arg and neutrophil dysfunc-
tions occur on a CU dialyser. These effects are attenu-
ated with the dialyser reuse as documented by others
and our earlier studies [7,14,15]. Furthermore, despite
a similar leukopenia at both venous and arterial sides,
the neutrophil functional alterations are evidenced only
after passage through the dialyser as we previously
reported [9]. The neutrophil dysfunctions observed
during dialysis have been attributed to downregulation
of the cells by activated complement resulting from
the passage of the blood through the dialyser mem-
brane [9]. However the present study shows that upon
pretreatment of CU with ALB or IG, the defects
observed in neutrophil functions at the venous site of
the dialyser were abolished while leukopenia and com-
plement activation were not modified. In contrast,
pretreatment of CU membrane with PLP corrected
both leukopenia and neutrophil dysfunctions, but not
complement activation. Furthermore, at the maximum
of complement activation and leukopenia, neutrophils
isolated at the arterial site were still functional, despite
higher accumulation of C3a des arg at the venous site
as early as 1 min [16,17]. The dissociation between the
various alterations is thus suggestive of complement-
dependent and complement-independent pathways
modulating leukopenia and neutrophil functions; other
proteins and the type of membrane must play an
additional role [9]. Indeed, in vitro studies have shown
that protein coating of cellulosic or synthetic mem-
branes with plasma did either stimulate or depress
neutrophil oxidative metabolism according to the type
of membrane [10], while coating the membranes
with albumin only depressed neutrophil oxidative
metabolism [17].
It was also recently reported that upon pretreatment
with albumin 25%, elastase accumulation was
decreased while complement activation was not modi-
fied [18]. In addition, accumulation of granulocyte
lactoferrin and myeloperoxidase in the plasma meas-
ured at the arterial site was not modified with reuse
despite a marked attenuation of complement activa-
tion, while the rise in elastase was decreased with
reuse [18].
These discrepant results about the protective effect
375
of protein coating on complement activation, leukop-
enia and neutrophil functions indicate that different
protein solutions are not sufficient to confer a similar
protection as plasma. This suggests that a specific
competitive and selective adsorption among different
types of proteins could confer these various protect-
ive effects.
In conclusion, the present study confirms that com-
plement activation is not the only possible pathway
leading to leukopenia and neutrophil functional altera-
tions on a cuprophan membrane. Selective protein
adsorption on the dialyser membrane interferes differ-
ently on several parameters of membrane bioincompat-
ibility: the nature of the membrane, the direct
neutrophil contact with the membrane, the protein
adsorption and as yet unknown factors could each
play a role, alone or in synergy.
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